GlassScriptPhysician profile
Betsy J Wernli
NPI 1437378973
$177,262.13
in general payments reported to CMS, 2019-2025
32 companies · $775 in 2025
The $775 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $14K · 2021: $16K · 2022: $17K · 2023: $3,784 · 2024: $98K · 2025: $775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $101K · Food and Beverage: $1,839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $100,550.91 |
| Food and Beverage | $1,838.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $101,256.88 | 2019-2025 | Rinvoq, Botox |
| Allergan, INC. | $39,348.75 | 2019-2022 | |
| Ucb, INC. | $32,501.44 | 2019-2022 | |
| Janssen Biotech, INC. | $812.06 | 2019-2023 | Tremfya |
| Novartis Pharmaceuticals Corporation | $562.89 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $302.95 | 2019-2021 | |
| Lilly USA, LLC | $286.55 | 2019-2024 | Taltz, Olumiant |
| Genzyme Corporation | $243.65 | 2019-2025 | |
| Dermavant Sciences, INC. | $216.31 | 2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $203.11 | 2019-2025 | Odomzo, Blu-U |
| E.R. Squibb & Sons, L.L.C. | $169.59 | 2022-2025 | Sotyktu |
| Biofrontera INC. | $156.20 | 2019-2022 | |
| Incyte Corporation | $155.33 | 2022-2024 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $151.28 | 2019-2022 | |
| Organon LLC | $124.91 | 2025 | Vtama |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $120.72 | 2019 | |
| Arcutis Biotherapeutics, INC. | $109.63 | 2023-2025 | Zoryve |
| Amgen INC. | $103.71 | 2019-2024 | Otezla |
| Galderma Laboratories, L.P. | $74.27 | 2020-2024 | Oracea |
| Genentech USA, INC. | $63.65 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.64 | 2022-2024 | Spevigo |
| Pfizer INC. | $42.45 | 2020 | |
| Kyowa Kirin, INC. | $33.17 | 2024 | |
| Leo Pharma INC. | $21.39 | 2024 | Adbry |
| Mimedx Group, INC. | $20.32 | 2024 | |
| Springworks Therapeutics, INC. | $19.58 | 2025 | Gomekli |
| Helsinn Therapeutics (U.S.), INC. | $19.45 | 2019 | |
| Strata Skin Sciences, INC. | $19.37 | 2024 | Xtrac |
| Almirall LLC | $18.90 | 2020 | |
| Prugen, INC. Pharmaceuticals | $17.01 | 2019 | |
| Nobelpharma America, LLC | $15.92 | 2025 | |
| Pierre Fabre Pharmaceuticals, INC. | $12.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Betsy Wernli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.